PMID- 32606637
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 15
DP  - 2020
TI  - Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 
      1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population.
PG  - 1245-1252
LID - 10.2147/COPD.S247377 [doi]
AB  - BACKGROUND: Severe alpha-1-antitrypsin deficiency (AATD) is an established risk 
      factor for chronic obstructive pulmonary disease (COPD) and liver disease, but 
      the effect on the incidence of ischemic heart disease (IHD) is not well known. 
      The aim was to evaluate the risk of incident IHD in patients with severe AATD 
      compared with a random sample of the general population, with known smoking 
      habits. METHODS: AAT-deficient individuals, phenotype PiZZ (n=1545), were 
      included in the Swedish National AATD Register. Controls (n=5883) were selected 
      from population-based cohorts in Northern Sweden. Data on IHD and comorbidities 
      were obtained by nationwide cross-linkage with the Swedish National Patient 
      Register. Risk factors for incident IHD were analyzed using Cox regression, 
      adjusted for age, gender, smoking status and the presence of COPD, hypertension, 
      hyperlipidemia and diabetes. RESULTS: At inclusion, 46% of the PiZZ individuals 
      and 53% of the controls were never-smokers. During follow-up (median 16 years; 
      range 0.2-23), 8% (n=123) of PiZZ individuals and 12% (n=690) of controls 
      developed IHD. The controls had a significantly higher risk for incident IHD than 
      the PiZZ individuals, with adjusted hazard ratio (HR) of 1.8 (95% CI 1.4-2.3). 
      The risk was higher for controls in both ever-smokers (HR 2.1; 95% CI 1.5-2.9) 
      and never-smokers (HR 1.5; 95% CI 1.1-2.2). CONCLUSION: PiZZ individuals have a 
      lower risk of developing incident ischemic heart disease than the control 
      subjects with known smoking habits, who had been randomly selected from 
      population-based cohorts.
CI  - (c) 2020 Tanash et al.
FAU - Tanash, Hanan
AU  - Tanash H
AD  - Departments of Respiratory Medicine, Skane University Hospital, Lund University, 
      Lund, Sweden.
FAU - Ekstrom, Magnus
AU  - Ekstrom M
AUID- ORCID: 0000-0002-7227-5113
AD  - Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine 
      and Allergology, Lund University, Lund, Sweden.
FAU - Basil, Nawfal
AU  - Basil N
AD  - Departments of Respiratory Medicine, Skane University Hospital, Lund University, 
      Lund, Sweden.
FAU - Ronmark, Eva
AU  - Ronmark E
AD  - Department of Public Health and Clinical Medicine, The OLIN Unit, Division of 
      Occupational and Environmental Medicine, Umea University, Umea, Sweden.
FAU - Lindberg, Anne
AU  - Lindberg A
AD  - Department of Public Health and Clinical Medicine, Division of Medicine, Umea 
      University, Umea, Sweden.
FAU - Piitulainen, Eeva
AU  - Piitulainen E
AD  - Departments of Respiratory Medicine, Skane University Hospital, Lund University, 
      Lund, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
RN  - 0 (alpha 1-Antitrypsin)
SB  - IM
MH  - Humans
MH  - *Myocardial Ischemia/diagnosis/epidemiology
MH  - *Pulmonary Disease, Chronic Obstructive/diagnosis/epidemiology
MH  - Smoking/adverse effects/epidemiology
MH  - Sweden/epidemiology
MH  - alpha 1-Antitrypsin
MH  - *alpha 1-Antitrypsin Deficiency/diagnosis/epidemiology
PMC - PMC7282800
OTO - NOTNLM
OT  - alpha-1-antitrypsin deficiency
OT  - chronic obstructive pulmonary disease
OT  - ischemic heart disease
OT  - smoking
COIS- Dr Anne Lindberg reports personal fees from Boehringer-Ingelheim, personal fees 
      from AstraZeneca, personal fees from Novartis, personal fees from 
      GlaxoSmithKline, outside the submitted work. The authors report no other conflict 
      of interest. The authors alone are responsible for the drafting as well as the 
      content of this study.
EDAT- 2020/07/02 06:00
MHDA- 2021/06/29 06:00
PMCR- 2020/06/04
CRDT- 2020/07/02 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/06/04 00:00 [pmc-release]
AID - 247377 [pii]
AID - 10.2147/COPD.S247377 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2020 Jun 4;15:1245-1252. doi: 
      10.2147/COPD.S247377. eCollection 2020.